Clinical Trials
45 trialsTesting the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy
National Cancer Institute (NCI)
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mayo Clinic
Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy
Canadian Cancer Trials Group
Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
CD70-targeted immunoPET Imaging of Malignant Cancers
RenJi Hospital
Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies
University of Washington
SOUND-MCL
AstraZeneca
Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
M.D. Anderson Cancer Center
A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
Beijing InnoCare Pharma Tech Co., Ltd.
A Study Comparing Rituximab/Bendamustin(RB) Alternating With Rituximab/Bendamustin/Cytarabin(RBAC) With RB Therapy in Elderly Patients With Mentle Cell Lymphoma
Samsung Medical Center
Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients
M.D. Anderson Cancer Center
Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma
Fred Hutchinson Cancer Center
Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
University of California, San Francisco
Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL
H. Lee Moffitt Cancer Center and Research Institute
Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma
City of Hope Medical Center
Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma
Peking University Third Hospital
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Fred Hutchinson Cancer Center
BRAZAN
Dana-Farber Cancer Institute
GLOASIS
The Lymphoma Academic Research Organisation
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
Emory University
Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma
Sun Yat-sen University
FIL_COLUMN
Fondazione Italiana Linfomi - ETS
Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
City of Hope Medical Center
Ultra Low Dose Radiation Delivered Before or After Chemotherapy-Free Targeted Therapy in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
M.D. Anderson Cancer Center
IMCL-2023
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease
Ruijin Hospital
Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas
University of Utah
Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
City of Hope Medical Center
Auto Stem Cell Transplant for Lymphoma Patients
Masonic Cancer Center, University of Minnesota
Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment
Ruijin Hospital
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Masonic Cancer Center, University of Minnesota
Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma
Sun Yat-sen University
DALY II USA/ MB-CART2019.1 for DLBCL
Miltenyi Biomedicine GmbH
ZEBRA
University College, London
CARAMEL
University College, London
Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma
University Health Network, Toronto
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
V-MIND
Academic and Community Cancer Research United
A Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell Lymphoma
Fudan University
CARMAN
Ludwig-Maximilians - University of Munich
Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma
Medical University of Vienna
Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma
Academic and Community Cancer Research United
GOlDiLOX
Australasian Leukaemia and Lymphoma Group
A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma
Ruijin Hospital
Ixazomib Maintenance in Patients With Newly Diagnosed Mantle Cell Lymphoma(MCL)
Kosin University Gospel Hospital